Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs KB Financial Group, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while KB Financial Group, Inc. trades at $122.87 (market cap $41.53B). The key difference: KB Financial Group, Inc. is far larger — about 5.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KB | |
|---|---|---|
Market Cap | $8.04B | $41.53B |
Sector | Health | Financials |
52-Week High | $339.75 | $123.25 |
52-Week Low | $241.71 | $77.50 |
Enterprise Value | $7.85B | — |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
KB Financial Group (KB) trades at $123.25, up 0.05% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, 27.82% net income margin, and 27.47% profit margin in 2025. Recent news highlights expansion into non-banking segments and dividend potential. Revenue grew to $21.23T in 2025, with net income reaching $5.83T.
The outlook remains positive with earnings growth and diversification driving upside, though technical oscillators signal overbought conditions. Risks include volatile cash flows and competitive pressures. Analyst consensus is mixed with 33% buy ratings. The stock presents value with a P/E of 11.84 but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
